3 results
Primary:• To compare the overall survival (OS) of patients in the rigosertib group vs the Physician*s Choice group, in all patients and in a subgroup of patients with IPSS-R very high riskSecondary efficacy• To compare rigosertib to Physician*s…
The purpose of this study is to assess whether a new combination treatment (Savolitinib and Durvalumab) is better than standard treatment sunitinib in MET-driven PRCC. The study will also assess the contribution of one part of the combination (…
Primary Objective: The performance in preventing intraoperative hypotension of a MAP treatment alarm of 72 mmHg compared to the performance of the HPI alarm. Secondary Objectives: - The correlation between the MAP signal and HPI signal - The…